Insights
Regulatory, sourcing, and quality for peptide buyers.
Briefings written for compounding pharmacy, med-aesthetic, distributor, and research-lab procurement teams. Updated monthly.
FDA PCAC July 2026: What 7 peptides under review mean for compounders
A buyer's briefing on BPC-157, TB-500, KPV, MOTs-C, Emideltide, Semax, and Epitalon — what changes, what doesn't, and how to prepare your sourcing pipeline.
Published May 16, 2026 · 6 min read
Read briefing
Sourcing GuideBPC-157 sourcing guide for compounding pharmacies
A buyer-side checklist for selecting a BPC-157 supplier: COA depth, sequence verification, regulatory awareness, and how to test before you scale.
Published May 12, 2026 · 5 min read
Read briefing
ComparisonTirzepatide vs. Retatrutide: a sourcing comparison
Side-by-side on regulatory status, sourcing complexity, vial-size availability, and how to choose between the two for your compounding pipeline.
Published May 8, 2026 · 8 min read
Read briefing
QualityReading a peptide COA: the buyer's field guide
What every line on a Certificate of Analysis means, which fields actually matter for your application, and how to spot a doctored document.
Published May 2, 2026 · 7 min read
Read briefing